Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AAV2/TNFR:Fc: Phase I/II data

TGEN said final molecular test results confirm that tgAAC94 did not contribute to the previously reported death in the company's Phase I/II rheumatoid arthritis

Read the full 246 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE